SCTX Stock — Scribe Therapeutics Inc. Common Stock

Scribe Therapeutics Inc. Common Stock (SCTX)

Updated October 16, 2026.

SCTX is a Stock. Total return is 33.9% over the past 0.2 years, 30.2 points ahead of SPY at 3.7%.

Scribe Therapeutics Inc. is a clinical-stage biotechnology company developing CRISPR-based genetic medicines targeting cardiometabolic diseases, with lead programs including epigenetic silencing and gene editing treatments for conditions involving elevated cholesterol and lipoprotein levels. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotechnology innovation, though it carries the risks inherent to clinical-stage development with no approved products generating revenue.

SCTX performance versus SPY

Price and return data through 2026-10-16.

Total return is 33.9% over the past 0.2 years, 30.2 points ahead of SPY at 3.7%.

SCTX key facts

Asset type

Stock

Asset class

Equity

Inception date

07/23/2026

Distribution frequency

None

Last close

$20.08 (as of 2026-10-16)

Market cap

$380,148,134

Average volume

201393.0

Payout ratio

0.0%

EPS

$-3.84

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider SCTX — and who may not

It is a weaker fit for investors who need monthly cash flow (SCTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on SCTX

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions